Understand functional low testosterone, associated health conditions and medicines, repeat testing, and why clinicians assess for organic causes.
Functional low testosterone means low testosterone associated with other health conditions or medicines when no recognised organic disorder of the hormone system has been found. The European Association of Urology (EAU) calls this functional hypogonadism and treats it as a diagnosis of exclusion. Clinicians must assess for organic causes rather than assume that obesity or another illness explains the result.
The term describes a different distinction from primary versus secondary hypogonadism. Primary hypogonadism involves impaired testicular function. Secondary hypogonadism involves inadequate stimulation from the hypothalamus or pituitary. Understanding these different patterns of low testosterone helps explain why finding the cause matters as much as confirming the result.
This article is for informational purposes and is not medical advice. A qualified clinician should assess symptoms and laboratory findings before making decisions about investigation or treatment.
A testosterone reference interval describes hormone concentrations measured in blood. It does not identify whether an underlying problem is functional or organic. Functional hypogonadism therefore does not have a separate numerical reference range that distinguishes it from gland disease.
In its Male Hypogonadism guideline, the EAU bases diagnosis on compatible signs or symptoms together with consistently low testosterone. A single below-range result is a starting point for evaluation rather than a complete diagnosis.
The guideline recommends:
SHBG stands for sex hormone-binding globulin. The EAU lists obesity and insulin resistance among factors associated with lower SHBG. This can complicate the interpretation of total testosterone and explains why clinicians sometimes assess the relationship between total testosterone and binding proteins.
The practical distinction is between confirming a low concentration and explaining it. Those are related tasks but not interchangeable ones. Our explanation of why confirmation uses separate morning samples provides more context for the testing discussion.
Low sexual desire is a concern worth discussing during an assessment for low testosterone. The EAU recommends prolactin testing when low sexual desire or other findings warrant investigation for secondary hypogonadism.
Sleep disturbance also appears in the guideline, but it is not specific to hypogonadism. A sleep complaint should not be treated as proof of a hormone disorder. Likewise, a sexual symptom does not establish that any low testosterone result is functional rather than organic.
It helps to separate the concern from the proposed explanation. Low sexual desire describes a symptom. Functional hypogonadism describes a clinical conclusion reached after testing and assessment of possible causes.
That distinction keeps the consultation focused on both questions: what needs attention and whether testosterone is part of the explanation. The EAU's diagnostic approach combines symptoms with repeat blood testing rather than using either alone.
The EAU identifies several health-related influences on the hormone system. Reviewing them is part of assessing the cause of low testosterone, not a reason to bypass investigation for testicular or pituitary disease.
The EAU identifies obesity and associated conditions, including diabetes, as major contributors to functional hypogonadism. It also reports that low testosterone is common in men with obesity.
There are two issues to consider. Obesity may be associated with changes affecting the hormone system itself. Lower SHBG can also affect how total testosterone is interpreted. A low total result therefore needs context rather than an explanation based on body weight alone.
For men with hypogonadism who are overweight or obese, the guideline recommends lifestyle changes and weight reduction as an initial approach. It describes the testosterone increase associated with a low-calorie diet and regular physical activity as small. The studies it discusses reported increases of about 1 to 2 nmol/L.
These findings support including weight and metabolic health in the assessment. They do not make body weight a substitute for the rest of the hormone evaluation.
The EAU reports a higher prevalence of late-onset hypogonadism in populations with obesity and type 2 diabetes. It also identifies associations with metabolic syndrome and cardiovascular disease. Other listed populations include men with chronic obstructive pulmonary disease, renal disease or cancer.
Its classification also includes chronic systemic disease and chronic organ failure among conditions that may affect the hormone system. These are associations across groups, not proof that a particular illness explains an individual man's result.
Acute illness raises a separate testing issue. The EAU advises against measuring testosterone during acute disease because illness can be associated with functional suppression. When a result was obtained while someone was unwell, an appropriate discussion is whether reassessment after recovery is needed.
A review of how broader health conditions fit into hormone assessment can help keep this conversation focused on overall health rather than one isolated result.
The EAU identifies opiates and glucocorticoids among medicines that can affect the hypothalamic-pituitary-testicular axis. This is the signalling system linking the brain and testes. Its classification also includes testosterone exposure and anabolic-androgenic steroid use.
The guideline recommends reviewing medicines and substances that may interfere with testosterone production or action. A clinical history should therefore include prescription medicines and non-prescription substances, along with previous anabolic steroid exposure.
When possible, clinicians may consider withdrawing a contributing medicine as part of management. That is not a recommendation to stop or change prescribed treatment independently. The review belongs with the clinician responsible for balancing the medicine's purpose against its possible hormonal effects.
Sleep matters to the circumstances of testing. The EAU notes that testosterone's daily rhythm is driven primarily by sleep patterns when discussing night-shift workers.
This makes work schedules and sleep patterns relevant information for the clinician arranging a blood sample. A clock-time label alone may leave out important context about when someone sleeps.
Sleep concerns also belong in the wider symptom discussion. They should be considered alongside health conditions and medicines rather than automatically assigned as the explanation for a low result.
The presence of a possible contributor does not finish the investigation. The EAU lists testicular trauma and surgery among organic causes of hypogonadism. Other examples include pituitary or hypothalamic tumours and traumatic brain injury.
The guideline recommends measuring luteinising hormone, or LH, and follicle-stimulating hormone, or FSH, to help distinguish types of hypogonadism. Prolactin testing is recommended in specified circumstances that raise concern for secondary hypogonadism.
Further investigation depends on the clinical pattern. The EAU recommends pituitary MRI in secondary hypogonadism when prolactin is raised or symptoms suggest a pituitary mass. Evidence of other anterior pituitary hormone deficiency is another indication.
These investigations serve a different purpose from confirming the testosterone concentration. They help clinicians assess the hormone system and decide whether a recognised organic disorder needs attention.
For appropriate patients, the EAU recommends addressing excess weight and relevant health conditions. It also recommends considering contributing medicines before testosterone therapy when changes are possible within clinical care.
The central limitation is that addressing a potentially modifiable factor does not reliably restore testosterone or replace indicated treatment. This applies to weight reduction and exercise as well as sleep-related changes and medication review. The guideline also notes that some weight regain occurs over time, so an improvement should not automatically be considered permanent.
Follow-up testing and symptom review help establish whether the clinical picture has changed. Functional does not mean that improvement is assured, just as secondary hypogonadism does not automatically mean a reversible problem.
The EAU separately recommends treating organic causes when indicated. Symptomatic men with low testosterone may be candidates for testosterone therapy if there are no specific contraindications. Fertility goals belong in that decision because testosterone therapy suppresses gonadotropins and the body's own testosterone secretion. It also suppresses sperm production.
Have my low results been confirmed with suitable repeat testing? Could my health conditions or medicines contribute, and which tests would help exclude an organic cause? How will we reassess symptoms and hormone results after addressing possible contributors? How do my fertility goals affect treatment choices?
Separating possible health-related testosterone changes from gland disorders leaves medical decisions with the clinician and gives Testostra a clear educational role. For men uncertain about symptoms and their possible causes, its evidence-led coverage explains low testosterone and related biomarkers to support a more informed discussion without assigning a diagnosis or prescribing treatment.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra